Trial Profile
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Mirogabalin (Primary)
- Indications Fibromyalgia; Pain
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Daiichi Sankyo Inc
- 31 Aug 2017 According to a Daiichi Sankyo media release, the results from the global clinical development program consisting of several phase 3 clinical trials, including NEUCOURSE, REDUCER and ALDAY, will serve as the basis for potential regulatory submissions in various countries.
- 30 Jun 2017 Status changed from active, no longer recruiting to completed, according to a Daiichi Sankyo media release.
- 30 Sep 2016 Study design and preliminary demographic data presented at the 16th World Congress on Pain.